Survival Outcomes of Wilms’ Tumor in Pediatric Patients Treated at KFMC
Janna Sisakyan, at
”15 years of data. One rare childhood cancer. Insights you can’t miss.
Our latest article in OncoDaily Medical Journal explores “Survival Outcomes of Wilms’ Tumor in Pediatric Patients Treated at KFMC: A Retrospective Study of 2007-2022.”
This study by Omer Alnour, Mohammed Rayis, Fahad Almanjomi, and Zaheer Ullah offers valuable real-world insights into long-term survival trends, treatment approaches, and clinical outcomes for pediatric Wilms’ tumor patients at King Fahad Medical City – KFMC, spanning more than a decade of care.
Highlights:
* 95.7% of patients are alive at final follow-up
* 88.3% remain relapse-free
* Median overall survival (OS) was 169.4 months
* Median recurrence-free survival (RFS) was 145.4 months
* Notable prevalence of advanced-stage disease (56% stage III/IV) and pulmonary metastasis (46.8%)
Why It Matters: This research emphasizes the importance of adhering to international treatment protocols, even in resource-limited settings. Early diagnosis, protocol-based care, and molecular prognostics are crucial to maintaining high survival rates in pediatric Wilms tumor patients.
Read the full article here.”
More posts featuring Janna Sisakyan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023